|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Malignant neoplasm of prostate
|
0.310 |
Biomarker
|
disease |
CTD_human |
Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.
|
19208208 |
2009 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.
|
19208208 |
2009 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Here we report that, in the tumor microenvironment of hepatocellular carcinoma (HCC), SPON2 not only promotes infiltration of M1-like macrophages but also inhibits tumor metastasis.
|
29440144 |
2018 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Spon2 is a proto-oncogene matrix protein that plays an essential role in the tumorigenesis and metastasis of gastric cancer.
|
28772159 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The spondin-2 correlated with tumor progression in many malignancies.
|
28060752 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Overall, our findings provide evidence that SPON2 is a critical factor in mediating the immune response against tumor cell growth and migration in HCC.<b>Significance:</b> Matricellular protein SPON2 acts as an HCC suppressor and utilizes distinct signaling events to perform dual functions in HCC microenvironment.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/9/2305/F1.large.jpg <i>Cancer Res; 78(9); 2305-17.©2018 AACR</i>.
|
29440144 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Spondin-2, belongs to the SOX (SRY-related HMG box) gene family, plays a vital role in the development of malignancy, however, the role of Spondin-2 in laryngeal squamous cell carcinoma (LSCC) remains unknown.
|
30527359 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curve analysis demonstrated that plasma Spondin-2 has superior predictive performance for CRC with an area under the curve of 0.959 and the best sensitivity/specificity of 100%/90%.
|
25945835 |
2015 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer.
|
27669439 |
2017 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In patients, SPON2 serves as prognostic indicator for CRC metastasis and survival, and might represent a promising target for therapeutic approaches.
|
26686083 |
2016 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Structure-based design of competitive ligands to target Spon2 in gastric cancer: An integration of molecular modeling and in vitro assay.
|
28772159 |
2017 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
However, the role of spondin-2 in gastric cancer has not been thoroughly elucidated.
|
28060752 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Overall, our findings provide evidence that SPON2 is a critical factor in mediating the immune response against tumor cell growth and migration in HCC.<b>Significance:</b> Matricellular protein SPON2 acts as an HCC suppressor and utilizes distinct signaling events to perform dual functions in HCC microenvironment.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/9/2305/F1.large.jpg <i></i>.
|
29440144 |
2018 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Recent studies have shown that SPON2 has complicated roles in cell migration and tumor progression.
|
29440144 |
2018 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Together, these experimental findings suggest that spondin 2, which is regulated by T(3), has an important role in cell invasion, cell migration, and tumor progression.
|
19903741 |
2010 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The spondin-2 correlated with tumor progression in many malignancies.
|
28060752 |
2017 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
However, the role of spondin-2 in gastric cancer has not been thoroughly elucidated.
|
28060752 |
2017 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Structure-based design of competitive ligands to target Spon2 in gastric cancer: An integration of molecular modeling and in vitro assay.
|
28772159 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells.
|
31691494 |
2020 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Overall, our findings provide evidence that SPON2 is a critical factor in mediating the immune response against tumor cell growth and migration in HCC.<b>Significance:</b> Matricellular protein SPON2 acts as an HCC suppressor and utilizes distinct signaling events to perform dual functions in HCC microenvironment.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/9/2305/F1.large.jpg <i></i>.
|
29440144 |
2018 |
|
Secondary Neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Spondin 2 (SPON2), a member of the Mindin F-Spondin family, identifies pathogens, activates congenital immunity and promotes the growth and adhesion of neurons as well as binding to their receptors, but its role in promoting or inhibiting tumour metastasis is controversial.
|
31691494 |
2020 |
|
Secondary Neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Here we report that, in the tumor microenvironment of hepatocellular carcinoma (HCC), SPON2 not only promotes infiltration of M1-like macrophages but also inhibits tumor metastasis.
|
29440144 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Spondin-2, belongs to the SOX (SRY-related HMG box) gene family, plays a vital role in the development of malignancy, however, the role of Spondin-2 in laryngeal squamous cell carcinoma (LSCC) remains unknown.
|
30527359 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Overall, our findings provide evidence that SPON2 is a critical factor in mediating the immune response against tumor cell growth and migration in HCC.<b>Significance:</b> Matricellular protein SPON2 acts as an HCC suppressor and utilizes distinct signaling events to perform dual functions in HCC microenvironment.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/9/2305/F1.large.jpg <i>Cancer Res; 78(9); 2305-17.©2018 AACR</i>.
|
29440144 |
2018 |